SOURCES SOUGHT
66 -- Fluor-de-Lys SIRT2 fluorometric drug discovery kit and Plate.
- Notice Date
- 6/5/2018
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- SBSS-N02RC82551-61
- Archive Date
- 6/26/2018
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov
(ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: June 11 2018 by 1:00PM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified small business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1000 employees is being considered. As a result of this Sources Sought Notice, the NCI may issue a combined synopsis solicitation through FedBizOpps. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. Proteomic profiling and hypothesis-driven investigations have identified mediators of acute radiation response in the mature central nervous system that may produce long-term, sustained proteomic alterations leading to neurodegeneration and functional decline. The NCI lab has also evaluated global changes in the brain and have suggested that sirtuin 2 (Sirt2), myelin oligodendrocyte glycoprotein (Mog), Microtubule associated protein tau (Mapt), Synaptosomal associated protein 25kDa (Snap25), and Dynamin 1 (Dnm1) play crucial roles in converting the acute, subcellular radiation response to long-term radiation toxicities. The NCI's focus is on the role of Sirtuin 2 (Sirt2), a class III histone deacetylase, in these processes. The NCI lab has shown that SIRT2 binds and deacetylates beta-catenin in a dose-dependent manner following exposure to ionizing radiation, and regulates expression the Wnt signaling pathway and cellular response to radiation-induced stress. Sirt2 regulates radiosensitivity and the DNA-damage response in rodent and human brain, and acts as a mediator of radioresistance in human glioma. These data are being correlated to patient outcomes evaluating serum and urine markers of CNS radiotoxicity that are evaluated by the NCI clinical protocol 08-C-0214, Neuropsychological outcome measures in patients receiving whole brain radiation. The NCI plans to screen for inhibitors of Sirt2 that could be used to evaluate radioprotection and/or mitigation from radiation injury in clinical trial. The National Cancer Institute (NCI) Center for Cancer Research (CCR), Radiation Oncology Branch (ROB) plans to screen for inhibitors of Sirt2 that could be used to evaluate radioprotection and/or mitigation from radiation injury in clinical trial. To this end, ROB intends to procure Fluor-de-Lys SIRT2 fluorometric drug discovery kit and Plate (white) (half-area with non-binding surface). The following product features/characteristics required are: •The results obtained shall be reproducible. •The inhibitors provided with the kit shall be able to inhibit the deacetylase activity of SIRT2. The inhibitors provided with the assay kit as negative controls shall be able to successfully inhibit the activity of SIRT2. •The solvent DMSO shall not interfere with either SIRT2 enzyme and/or substrate. It shall not generate false fluorescence reading when used alone. •The assay shall not show any interference from enzyme or substrate alone on the fluorescence readings. •One of the known inhibitors of SIRT2 deacetylase activity is the compound, AGK2. Assay shall show successful inhibition of SIRT2 deacetylase activity. •The kit shall offer a standard curve to check for the interference of the drug screened with the developer. Delivery: Delivery shall be within 4 - 6 weeks of purchase order award. All shipping/handling and delivery fees shall be included. How to Submit a Response: 1. Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12 point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 2. Due Date: Capability statements are due no later than 1:00PM EST on June 11, 2018. 3. Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. Written responses can be emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov or mailed to the address located under Point of Contact. All questions must be in writing and can be faxed to (240) 276-5399 or emailed. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference number SBSS- N02RC82551-61 on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be published on FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: Kathy Elliott 9609 Medical Center Dr., Room 1E226 Bethesda, MD 20892-9705 Elliottk@mail.nih.gov
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/SBSS-N02RC82551-61/listing.html)
- Place of Performance
- Address: 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04943648-W 20180607/180605230933-99c19b5ce73d60b2452aa2cfe58a13d2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |